Efficiency of instillation methods for prostaglandin medications

Journal of Ocular Pharmacology and Therapeutics

Volumn 22, Issue 6, 2006, Pages 477-482

  Fiscella, Richard ^a   Wilensky, Jacob T ^a   Chiang, Tina H ^b   Walt, John G ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; EYE DROPS; LATANOPROST; PROSTAGLANDIN; TRAVOPROST;

ARTICLE; COST CONTROL; DRUG COST; DRUG INSTILLATION; GLAUCOMA; STATISTICAL ANALYSIS; TECHNIQUE;

AMIDES; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; COST-BENEFIT ANALYSIS; INSTILLATION, DRUG; LIPIDS; MODELS, THEORETICAL; PROSTAGLANDINS F, SYNTHETIC;

EID: 33846228902     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2006.22.477     Document Type: Article

References (17)

1. The Advanced Glaucoma Intervention Study (AGIS). 7. The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 130:429-440, 2000.
2. Fiscella, R.G. Pharmacological considerations in the treatment of glaucoma. Manag. Care 11(Suppl. 1):16-20, 2002.
3. Fiscella, R.G. Glaucoma medications: A drug-therapy review. Manag. Care 11(Suppl. 11):25-31, 2002.
4. Kass, M.A., Heuer, D.K., Higginbotham, E.J., et al. The Ocular Hypertension Treatment Study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120:701-713, 2002.
5. Hedman, K., and Alm, A. A pooled-data analysis of three randomized, double-masked, 6-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur. J. Ophthalmol. 10:95-104, 2000.
6. Fellman, R.L., Sullivan, E.K., Ratliff, M., et al., and the Travoprost Study Group. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: A 6-month, masked, multicenter trial. Ophthalmology 109:998-1008, 2002.
7. Cohen, J.S., Gross, R.L., Cheetham, J.K., et al. Two-year, double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv. Ophthalmol. 49(Suppl. 1):S45-S52, 2004.
8. Tsai, J.C., McClure, C.A., Ramos, S.E., et al. Compliance barriers in glaucoma: A systematic classification. J. Glaucoma 12:393-398, 2003.
9. Jampel, H.D., Parekh, P., Johnson, E., et al. Preferences for eye drop characteristics among glaucoma specialists: A willingness-to-pay analysis. J. Glaucoma 14:151-156, 2005.
10. Olthoff, C.M., Schouten, J.S., van de Borne, B.W., et al. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology 112:953-961, 2005.
11. Mick, A.B., Gonzalez, S., Dunbar, M.T., et al. A cost analysis of the prostaglandin analogs. Optometry 73:614-619, 2002.
12. Fiscella, R.G., Green, A., Patuszynski, D.H., et al. Medical therapy cost considerations for glaucoma. Am. J. Ophthalmol. 136:18-25, 2003.
13. Walt, J.G., and Lee, J.T. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension. Surv. Ophthalmol. (49 Suppl. 1):S36-S44, 2004.
14. Van Santvliet, L., and Ludwig, A. Determinants of eye drop size. Surv. Ophthalmol. 49:197-213, 2004.
15. Eter, N., and Gobbels, M. A new technique for tear film fluorophotometry. Br. J. Ophthalmol. 86:616-619, 2002.
16. Yokoi, N., Bron, A.J., Tiffany, J.M., et al. Relationship between tear volume and tear meniscus curvature. Arch. Ophthalmol. 122:1265-1269, 2004.
17. Fiscella, R.G., Geller, J.L., Gryz, L.L., et al. Cost considerations of medical therapy for glaucoma. Am. J. Ophthalmol. 128:426-433, 1999.